糖尿病治療市場規模、佔有率和成長分析：按疾病類型、藥物類別、給藥途徑、分銷管道、最終用戶和地區分類－2026-2033年產業預測

2024 年全球糖尿病治療市場價值為 952 億美元，預計到 2025 年將成長至 2033 年的 2,300.5 億美元，預測期（2026-2033 年）複合年成長率為 10.3%。

全球糖尿病治療市場正經歷強勁成長，這主要得益於糖尿病盛行率的上升以及創新降血糖療法的普及。人們對糖尿病管理的認知不斷提高，加上生物製藥和注射藥物的進步，推動了市場銷售。胰島素類似物、GLP-1受體促效劑和SGLT2抑制劑的廣泛應用，以及聯合治療的激增，進一步促進了市場擴張。此外，對生物製藥和數位健康技術（例如持續血糖監測和智慧胰島素輸注系統）的大量投資有望改善治療效果並提高患者依從性。儘管高成本、部分地區獲取途徑有限以及嚴格的監管等挑戰可能會阻礙市場滲透，但對有效且個人化治療的追求仍然是推動成長要素。

全球糖尿病治療市場按疾病類型、藥物類別、給藥途徑、分銷管道、最終用戶和地區進行細分。依疾病類型分類，市場分為第1型糖尿病、第2型糖尿病和妊娠糖尿病。依藥物類別分類，市場分為胰島素、雙胍類、磺醯尿素類、DPP-4抑制劑、GLP-1受體促效劑、SGLT2抑制劑、胰島素增敏劑（TZDs）、α-Glucosidase酶抑制劑、Meglitinides及其他藥物。依給藥途徑分類，市場分為口服和注射給藥。按分銷管道分類，市場分為醫院藥房、零售藥房和線上藥房。依最終用戶分類，市場分為醫院、糖尿病專科診所、居家醫療和門診手術中心（ASC）。依地區分類，市場分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。

全球糖尿病治療市場的成長要素

隨著全球糖尿病發生率的上升，對有效藥物治療的需求日益成長，製藥公司正不斷擴大研發規模，並增加對創新製劑開發的投資。全球人口老化和久坐生活方式的盛行，也使得不同臨床環境下對多樣化治療方案的需求不斷增加。這些變化促使製造商拓展產品線，強化分銷網路，以滿足患者日益成長的需求。因此，在對新療法的需求以及讓更多人能夠獲得治療的推動下，糖尿病治療市場也在不斷發展演變。

全球糖尿病治療市場阻礙因素

新上市的糖尿病藥物價格高昂，對患者和醫療保險公司都構成了重大挑戰，儘管這些藥物療效顯著，但其使用卻受到限制。高額的自付費用阻礙了患者尋求這些治療，有時甚至迫使醫生轉而使用價格較低廉的舊藥。此外，保險公司可能透過處方藥清單和預先核准要求來限制藥物的獲取，進一步阻礙了這些產品的市場准入。因此，這些藥物帶來的經濟負擔成為一大障礙，抑制了需求成長，並阻礙了糖尿病藥物市場的整體產生收入。

全球糖尿病治療市場趨勢

全球糖尿病治療市場正經歷著向個人化治療的重大轉變，個人化治療方案逐漸取代標準化治療方案。這一趨勢的驅動力來自基因譜分析和生物標記發現技術的進步，使製藥公司能夠開發針對特定患者亞群的標靶治療。這些創新技術能夠幫助醫療專業人員最佳化治療方案，進而提高治療效果、減少副作用並改善患者依從性。因此，市場對伴隨診斷和靈活給藥方案的關注度日益提高，反映出人們對滿足每位患者個別需求的客製化糖尿病管理解決方案的需求不斷成長。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 宏觀經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球糖尿病藥物市場規模：依疾病類型分類

• 1型糖尿病
• 2型糖尿病
• 妊娠糖尿病

全球糖尿病藥物市場規模：依藥物類別分類

• 胰島素
• 雙胍類藥物
• 磺醯尿素類藥物
• DPP-4抑制劑
• GLP-1受體促效劑
• SGLT2抑制劑
• 胰島素增敏劑藥物（TZDs）
• α-Glucosidase酶抑制劑
• Meglitinides類藥物
• 其他

全球糖尿病藥物市場規模：依給藥途徑分類

• 口服
• 注射藥物

全球糖尿病藥物市場規模：按分銷管道分類

• 醫院藥房
• 零售藥房
• 網路藥房

全球糖尿病藥物市場規模：依最終用戶分類

• 醫院
• 糖尿病專科診所
• 居家醫療
• 門診手術中心（ASC）

全球糖尿病藥物市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Novo Nordisk A/S
• Eli Lilly and Company
• Sanofi
• Merck & Co., Inc.
• AstraZeneca PLC
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Takeda Pharmaceutical Company Limited
• Novartis AG
• Pfizer Inc.
• Bayer AG
• Abbott Laboratories
• Oramed Pharmaceuticals Inc.
• vTv Therapeutics Inc.
• MannKind Corporation
• Lexicon Pharmaceuticals, Inc.
• Hanmi Pharmaceutical Co., Ltd.
• Dong-A ST Co., Ltd.
• Biocon Limited
• Julphar Gulf Pharmaceutical Industries

結論與建議

Global Diabetes Drugs Market size was valued at USD 95.2 Billion in 2024 and is poised to grow from USD 105.01 Billion in 2025 to USD 230.05 Billion by 2033, growing at a CAGR of 10.3% during the forecast period (2026-2033).

The global diabetes drugs market is experiencing robust growth, fueled by the rising prevalence of diabetes and a shift toward innovative glucose-lowering therapies. Enhanced awareness surrounding diabetes management, along with advancements in biologic and injectable drugs, is boosting sales. The increasing use of insulin analogues, GLP-1 receptor agonists, and SGLT2 inhibitors, combined with a surge in combination therapies, is further propelling market expansion. Additionally, significant investments in biologics and digital health technologies, such as continuous glucose monitoring and smart insulin delivery systems, are expected to enhance treatment outcomes and patient compliance. While challenges like high costs, limited access in some regions, and stringent regulations may hinder market penetration, the pursuit of effective and personalized treatment options remains a primary growth driver.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Diabetes Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Diabetes Drugs Market Segments Analysis

Global diabetes drugs market is segmented by disease type, drug class, route of administration, distribution channel, end user, and region. Based on disease type, the market is segmented into Type 1 Diabetes, Type 2 Diabetes, and Gestational Diabetes. Based on drug class, the market is segmented into insulin, biguanides, sulfonylureas, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors, Thiazolidinediones (TZDs), Alpha-Glucosidase Inhibitors, Meglitinides, and others. Based on route of administration, the market is segmented into oral and injectable. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Based on end user, the market is segmented into hospitals, specialty diabetes clinics, home care settings, and ambulatory surgical centers (ASCs). Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Driver of the Global Diabetes Drugs Market

The rise of diabetes worldwide has intensified the need for effective pharmacological treatments, prompting pharmaceutical companies to broaden their research portfolios and invest significantly in innovative formulations. As the global population ages and lifestyles become more sedentary, there is a greater demand for diverse treatment options across various clinical settings. This shifting landscape encourages manufacturers to expand their product offerings and enhance distribution networks to meet the growing needs of patients. Consequently, the market for diabetes drugs is continually evolving, driven by the imperative to develop new therapies and ensure that treatments are readily accessible to a wider audience.

Restraints in the Global Diabetes Drugs Market

The high expense associated with newly launched diabetes medications poses a significant challenge for both patients and health insurance providers, limiting their use despite the advantages these drugs offer. Elevated out-of-pocket costs often deter individuals from seeking these treatments, prompting physicians to revert to older, more affordable alternatives. Additionally, insurance companies may impose restrictions on access through formularies and prior authorization requirements, further complicating market entry for these products. Consequently, the financial implications of these medications create barriers that inhibit demand growth and hinder overall revenue generation within the diabetes drug market.

Market Trends of the Global Diabetes Drugs Market

The Global Diabetes Drugs market is experiencing a significant shift towards personalized therapy, prioritizing individualized treatment regimens over standardized approaches. This trend is driven by advancements in genetic profiling and biomarker discovery, which allow pharmaceutical companies to develop targeted agents tailored to specific patient subpopulations. By enabling healthcare providers to optimize treatment plans, these innovations enhance therapeutic efficacy, minimize adverse effects, and improve patient adherence. As a result, the market is witnessing a growing emphasis on companion diagnostics and flexible dosing options, reflecting the rising demand for customized diabetes management solutions that cater to unique patient needs.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Diabetes Drugs Market Size by Disease Type & CAGR (2026-2033)

• Market Overview
• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes

Global Diabetes Drugs Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Insulin
• Biguanides
• Sulfonylureas
• DPP-4 Inhibitors
• GLP-1 Receptor Agonists
• SGLT2 Inhibitors
• Thiazolidinediones (TZDs)
• Alpha-Glucosidase Inhibitors
• Meglitinides
• Others

Global Diabetes Drugs Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable

Global Diabetes Drugs Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Diabetes Drugs Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Diabetes Clinics
• Home Care Settings
• Ambulatory Surgical Centers (ASCs)

Global Diabetes Drugs Market Size & CAGR (2026-2033)

• North America (Disease Type, Drug Class, Route of Administration, Distribution Channel, End User)
  • US
  • Canada
• Europe (Disease Type, Drug Class, Route of Administration, Distribution Channel, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease Type, Drug Class, Route of Administration, Distribution Channel, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease Type, Drug Class, Route of Administration, Distribution Channel, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease Type, Drug Class, Route of Administration, Distribution Channel, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Novo Nordisk A/S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim International GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oramed Pharmaceuticals Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• vTv Therapeutics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MannKind Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lexicon Pharmaceuticals, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hanmi Pharmaceutical Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dong-A ST Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Julphar Gulf Pharmaceutical Industries
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations